Myriad Genetics Inc at Bank of America Merrill Lynch Health Care Conference Transcript
Well, great to have our next session here with Myriad. We have CEO (sic) [CFO], Bryan, and Scott from the IR joining us today. Great to have you guys. Well, on behalf of my senior analyst, Derik De Bruin, just wanted to give everyone greeting for and thank you for being here.
Without further ado, let's have Bryan give us a brief outline and recap the quarter maybe.
Great. Thanks, Ivy. Thank you for hosting. We really appreciate the opportunity to be here.
First of all, at Myriad, we're really focused on 5 strategic priorities. The first of those is to create a stable hereditary cancer business and maintain a stable business. We believe we made great strides there. We've had 2 consecutive quarters of 4% year-over-year growth, which I think the first one was the first time in 4 or 5 years that we had seen that business grow on a year-over-year basis. And we've increasingly seen positive signs in that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |